SNMMI: Study Shows Viability of FAPI PET/CT for Predicting Progressive Pulmonary Fibrosis in Lung Disease Patients
For patients with interstitial lung disease, FAPI PET/CT was more effective than 18F-FDG PET/CT at predicting progressive pulmonary fibrosis according to comparative study findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Emerging research suggests that fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) may be more advantageous than 18F-FDG PET/CT for early detection of progressive pulmonary fibrosis (PPF) in patients with interstitial lung disease (ILD).
In the comparative study, presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers reviewed pulmonary function tests and imaging data from 97 patients with ILD who had FAPI PET/CT and 18F-FDG PET/CT.
While both imaging modalities demonstrated an 89 percent specificity rate for predicting PPF, the researchers found that FAPI PET/CT had a significantly higher area under the curve (AUC) than 18F-FDG PET/CT (98 percent vs. 81 percent) and a 33 percent higher sensitivity rate (100 percent vs. 67 percent).
Here one can see 18F-FDG PET/CT and FAPI PET/CT imaging in a 46-year-old man one month after diagnosis of interstitial lung disease (ILD). For this patient, there was an SUVmax (yellow arrow) of 8.3 on FAPI PET/CT in contrast to 4.2 on 18F-FDG PET/CT. (Images courtesy of SNMMI.)
“While 18F-FDG PET/CT can offer some information about ILDs, FAPI PET/CT could provide even more information to physicians, especially regarding progressive pulmonary fibrosis. This could make it a promising diagnostic tool,” noted lead study author Qi Fang, M.D., a resident in the Department of Nuclear Medicine at Guangzhou Medical University in Guangzhou, China.
The researchers noted the whole lung SUVmean (WL-SUVmean) was a key differentiating parameter. Overall, the WL-SUVmean was significantly higher with FAPI PET/CT in comparison to 18F-FDG PET/CT (1.04 vs. 0.82). Patients with PFF demonstrated a higher WL-SUVmean than those without PPF (1.24 vs. 0.73), according to the study authors.
Fang and colleagues suggested the WL-SUVmean could be a “pivotal parameter” with FAPI PET/CT as a key source of metabolic information in patients with ILD.
“These findings underscore the potential utility of FAPI PET/CT as an imaging modality for diagnosing ILD,” said Fang. “In particular, our research shows that patients with high whole-lung SUVmean on FAPI scans tend to manifest progressive pulmonary fibrosis one year later. As such, these patients should be more carefully treated, and anti-fibrosis treatment should begin as early as possible.”
(Editor’s note: For additional content from the SNMMI conference, click here.)
Reference
1. Fang Q, Zhao R, Cui J, et al. Comparative analysis of FDG and FAPI PET/CT imaging in interstitial lung disease: focused on progressive pulmonary fibrosis prediction. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm?pgid=1579&RunRemoveSessionFilter=1 . Accessed June 8, 2024.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
